In recent years, both P&G and DuPont have conducted extensive research on human commensals to help address metabolic health issues in humans. To accelerate the development and commercialisation of NGPs, both companies are joining forces to develop NGPs, initially to be used in dietary supplements.

There is an increasing number of studies that have shown that diet and poor lifestyle choices negatively affect the gut microbiota, which can result in chronic low-grade inflammation which is closely associated with the onset and prevalence of metabolic health related conditions.

On the contrary, increasing levels of certain anaerobic bacteria in the gut has been shown to increase insulin sensitivity and thus helps to maintain healthy blood sugar levels.

“It’s an exciting opportunity to partner with P&G to jointly develop the next generation of microbe-based products. The combination of DuPont’s and P&G’s unique set of capabilities will allow us to accelerate innovation in the field of metabolic health and help millions of consumers affected by metabolic health issues,” said Sebastien Guery, Human Microbiome Venture leader, DuPont Nutrition & Biosciences.

“As a company focused on innovation, P&G is excited to come together with our valued partners at DuPont. Many consumers trust Align, the #1 doctor and gastroenterologist recommended probiotic brand, to promote and support a healthy digestive system."

This strategic partnership will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world” said Paul Gama, president, P&G Personal Health Care.